Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression.

The transition from stable to rupture-prone and ruptured atherosclerotic plaques involves many processes, including an altered balance between inflammation and fibrosis. An important mediator of both is transforming growth factor (TGF)-&bgr;, and a pivotal role for TGF-&bgr; in atherogenesis has been postulated. Here, we determine the in vivo effects of TGF-&bgr; inhibition on plaque progression and phenotype in atherosclerosis. Recombinant soluble TGF-&bgr; receptor II (TGF&bgr;RII:Fc), which inhibits TGF-&bgr; signaling, was injected in apolipoprotein E-deficient mice for 12 weeks (50 &mgr;g, twice a week intraperitoneally) as early treatment (treatment age 5 to 17 weeks) and delayed treatment (age 17 to 29 weeks). In the early treatment group, inhibition of TGF-&bgr; signaling treatment resulted in a prominent increase in CD3- and CD45-positive cells in atherosclerotic lesions. Most profound effects were found in the delayed treatment group. Plaque area decreased 37.5% after TGF&bgr;RII:Fc treatment. Moreover, plaque morphology changed into an inflammatory phenotype that was low in fibrosis: lipid cores were 64.6% larger, and inflammatory cell content had increased 2.7-fold. The amount of fibrosis decreased 49.6%, and intraplaque hemorrhages and iron and fibrin deposition were observed frequently. TGF&bgr;RII:Fc treatment did not result in systemic effects. These results reveal a pivotal role for TGF-&bgr; in the maintenance of the balance between inflammation and fibrosis in atherosclerotic plaques.

[1]  A. Chait,et al.  Proteoglycans Synthesized by Arterial Smooth Muscle Cells in the Presence of Transforming Growth Factor‐&bgr;1 Exhibit Increased Binding to LDLs , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[2]  M. Daemen,et al.  CD40-CD40L interactions in atherosclerosis. , 2002, Trends in cardiovascular medicine.

[3]  J. Mehta,et al.  Transforming Growth Factor-β1 Modulates Oxidatively Modified LDL–Induced Expression of Adhesion Molecules: Role of LOX-1 , 2001 .

[4]  E. Lutgens,et al.  Transforming growth factor-beta: a local or systemic mediator of plaque stability? , 2001, Circulation research.

[5]  A. Tedgui,et al.  Inhibition of Transforming Growth Factor- Signaling Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Mice , 2001 .

[6]  Naftali Kaminski,et al.  TGF-β is a critical mediator of acute lung injury , 2001 .

[7]  A. Grace,et al.  Microsatellite Mutation of Type II Transforming Growth Factor-&bgr; Receptor Is Rare in Atherosclerotic Plaques , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[8]  J. Schwartz,et al.  Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. , 2001, The American journal of cardiology.

[9]  Werner Poewe,et al.  Chronic Infections and the Risk of Carotid Atherosclerosis: Prospective Results From a Large Population Study , 2001, Circulation.

[10]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[11]  N. Kaminski,et al.  TGF-beta is a critical mediator of acute lung injury. , 2001, The Journal of clinical investigation.

[12]  V. Koteliansky,et al.  Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. , 2000, Gastroenterology.

[13]  J. Massagué,et al.  TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders , 2000, Cell.

[14]  M. Gimbrone,et al.  Inhibition of E-Selectin Gene Expression by Transforming Growth Factor β in Endothelial Cells Involves Coactivator Integration of Smad and Nuclear Factor κB–Mediated Signals , 2000, The Journal of experimental medicine.

[15]  Hong Wang,et al.  Transforming Growth Factor-β1 Inhibits Cytokine-mediated Induction of Human Metalloelastase in Macrophages* , 2000, The Journal of Biological Chemistry.

[16]  D. Grainger,et al.  Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. , 2000, Journal of cell science.

[17]  M. Daemen,et al.  Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Libby,et al.  Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Dichek,et al.  Cardiovascular overexpression of transforming growth factor-beta(1) causes abnormal yolk sac vasculogenesis and early embryonic death. , 2000, Circulation research.

[20]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[21]  R. Virmani,et al.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[22]  T. McCaffrey.  TGF-s and TGF- receptors in atherosclerosis , 2000 .

[23]  R. Flavell,et al.  Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease , 2000 .

[24]  R. Flavell,et al.  Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. , 2000, Immunity.

[25]  T. McCaffrey.  TGF-betas and TGF-beta receptors in atherosclerosis. , 2000, Cytokine & growth factor reviews.

[26]  V. Koteliansky,et al.  Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. , 2000, The American journal of pathology.

[27]  M. Territo,et al.  Interleukin-10 blocks atherosclerotic events in vitro and in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[28]  M. Daemen,et al.  Requirement for CD154 in the progression of atherosclerosis , 1999, Nature Medicine.

[29]  T. McCaffrey,et al.  The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. , 1999, Journal of molecular and cellular cardiology.

[30]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[31]  M. Condron,et al.  Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. , 1999, Circulation.

[32]  V. Koteliansky,et al.  Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. , 1999, Circulation research.

[33]  P. Schirmacher,et al.  TGF-β1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[34]  A. Tedgui,et al.  Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  R. Virmani,et al.  Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Ross,et al.  Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. , 1998, The American journal of pathology.

[37]  M J Davies,et al.  Relation of plaque lipid composition and morphology to the stability of human aortic plaques. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[38]  A. Tall,et al.  IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. , 1997, The Journal of clinical investigation.

[39]  D. Grainger,et al.  Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. , 1997, Circulation.

[40]  Kopp Jb.  Gene expression in kidney using transgenic approaches. , 1997 .

[41]  J. Kopp.  Gene expression in kidney using transgenic approaches. , 1997, Experimental nephrology.

[42]  W D Wagner,et al.  A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[43]  A. Grace,et al.  The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis , 1995, Nature Medicine.

[44]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[45]  J. Isner,et al.  Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. , 1992, The Journal of clinical investigation.

[46]  S. Schwartz,et al.  Production of transforming growth factor beta 1 during repair of arterial injury. , 1991, The Journal of clinical investigation.

[47]  P. Libby,et al.  Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[48]  M. Sporn,et al.  Transforming growth factor beta. , 1988, Advances in cancer research.